University of California

State of Oregon

Cocensys Inc.

Other

Acea Pharmaceuticals, Inc.

Sunil Kher

Sui Xiong Cai

Eckard Weber

John F Keana

John F W Keana

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.

Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist

Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalinediones

Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

Growing community of inventors

Eugene, OR, United States of America

Sunil Kher